Nexium ulcer approval
This article was originally published in The Tan Sheet
AstraZeneca receives EU approval to market prescription proton pump inhibitor Nexium for the treatment of gastric ulcers and prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory (NSAID) therapy, firm announces Sept. 16. Research into the treatment of NSAID-associated upper GI side effects demonstrated that Nexium "can effectively heal gastric ulcers and prevent gastric and duodenal ulcers associated with long-term NSAID use, as well as relieve other painful upper GI symptoms such as epigastric pain, heartburn and acid reflux," according to Nexium NSAID program lead investigator Chris Hawkey, University Hospital, Nottingham, England. AstraZeneca applied for the same indications for Nexium in the U.S. earlier this year...
You may also be interested in...
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
Fresenius Kabi must pay Eli Lilly €28m in damages after a French court of first instance found that the generics firm’s pemetrexed infringed intellectual property protecting the Alimta chemotherapy brand. The German firm has commented on possible next steps.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.